TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 18832520

Group type: EXPERIMENTAL
Intervention: Once daily (OD) 3 g mesalazine granules
Number of subjects: 380

Group type: COMPARATOR
Intervention: Three times daily (TID) 1 g mesalazine granules
Number of subjects: 380

Group type: EXPERIMENTAL
Intervention: Both OD and TID groups
Number of subjects: 380
Study: 17904962

Group type: EXPERIMENTAL
Intervention: Metronidazole plus azithromycin every 4 months
Number of subjects: 124

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 124
Study: 14739800

Group type: EXPERIMENTAL
Intervention: Supplemental oxygen administration adjusted to arterial oxygen tensions of approximately 150 mmHg
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Supplemental oxygen administration adjusted to arterial oxygen tensions of approximately 300 mmHg
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Postoperative tissue oxygen measurement adjacent to the wound
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Postoperative tissue oxygen measurement in the upper arm
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: First postoperative morning measurements
Number of subjects: 46
Study: 15848976

Group type: EXPERIMENTAL
Intervention: Sugar-free chewing gum in addition to oral health education (Group G)
Number of subjects: 1342

Group type: EXPERIMENTAL
Intervention: Oral health education (Group E)
Number of subjects: 1342

Group type: COMPARATOR
Intervention: Control group (Group C)
Number of subjects: 1342
Study: 10511361

Group type: EXPERIMENTAL
Intervention: Transdermal glyceryl trinitrate
Number of subjects: 60

Group type: COMPARATOR
Intervention: Intravenous ritodrine
Number of subjects: 60
Study: 7867351

Group type: EXPERIMENTAL
Intervention: Septic patients
Number of subjects: 17

Group type: COMPARATOR
Intervention: Controls
Number of subjects: 17
Study: 1959195

Group type: EXPERIMENTAL
Intervention: Nisoldipine 10 mg twice daily
Number of subjects: 185

Group type: EXPERIMENTAL
Intervention: Nisoldipine 5 mg twice daily
Number of subjects: 185

Group type: EXPERIMENTAL
Intervention: Nisoldipine 5 mg and 10 mg twice daily
Number of subjects: 185

Group type: EXPERIMENTAL
Intervention: Nisoldipine 2.5 mg, 5 mg, 10 mg twice daily
Number of subjects: 185

Group type: EXPERIMENTAL
Intervention: Nisoldipine 2.5 mg and 5 mg twice daily
Number of subjects: 185

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 185
Study: 7048037

Group type: EXPERIMENTAL
Intervention: Fentanyl
Number of subjects: 200

Group type: COMPARATOR
Intervention: Diazepam
Number of subjects: 200
Study: 30383184

Group type: EXPERIMENTAL
Intervention: Durvalumab (20 mg/kg every 4 weeks) + tremelimumab (1 mg/kg every 4 weeks for 4 cycles, followed by durvalumab (10 mg/kg every 2 weeks))
Number of subjects: 267

Group type: EXPERIMENTAL
Intervention: Durvalumab (10 mg/kg every 2 weeks) monotherapy
Number of subjects: 267

Group type: EXPERIMENTAL
Intervention: Tremelimumab (10 mg/kg every 4 weeks for 7 doses then every 12 weeks for 2 doses) monotherapy
Number of subjects: 267
Study: 25400009

Group type: EXPERIMENTAL
Intervention: Er:YAG AFL MAL‐PDT
Number of subjects: 33

Group type: COMPARATOR
Intervention: MAL‐PDT
Number of subjects: 33
Study: 23612222

Group type: EXPERIMENTAL
Intervention: Pragmatic exercise intervention (10 weeks, 2 supervised and 1 home-based session per week)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 30
Study: 21208264

Group type: EXPERIMENTAL
Intervention: CPR skills testing during the final half-hour of the course
Number of subjects: 146

Group type: COMPARATOR
Intervention: Additional training (control group)
Number of subjects: 146

Group type: EXPERIMENTAL
Intervention: Cortisol increase measured pre-course, half an hour before the end of the course, and post-course
Number of subjects: 146
Study: 19752423

Group type: EXPERIMENTAL
Intervention: AREDS 9-step severity scale
Number of subjects: 1001
Study: 17604473

Group type: EXPERIMENTAL
Intervention: Clofibate (100 mg/kg single oral dose)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control (distilled water)
Number of subjects: 60
Study: 15559871

Group type: EXPERIMENTAL
Intervention: Losartan 100 mg daily
Number of subjects: 85

Group type: COMPARATOR
Intervention: Enalapril 20 mg daily
Number of subjects: 85
Study: 11928160

Group type: EXPERIMENTAL
Intervention: Support group interventions co-led by peers and professionals
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Professional facilitators
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Peer facilitators
Number of subjects: 21
Study: 9710357

Group type: EXPERIMENTAL
Intervention: hP-16 (10 pmol/kg/min)
Number of subjects: 6
Study: 8062939

Group type: EXPERIMENTAL
Intervention: Cetrorelix 5 mg (group 1)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Cetrorelix 3 mg (group 2)
Number of subjects: 10
Study: 29648859

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: Alliance focused therapy
Number of subjects: 107

Group type: COMPARATOR
Intervention: Therapists' ratings of the alliance
Number of subjects: 107
Study: 27062069

Group type: EXPERIMENTAL
Intervention: Group psychotherapy + lodenafil 80 mg/one tablet per week (Group 4)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Group psychotherapy (Group 2)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Lodenafil 80 mg/one tablet per week (Group 3)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Control group (Group 1)
Number of subjects: 56
Study: 26704522

Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Number of subjects: 0

Group type: COMPARATOR
Intervention: MaxFib
Number of subjects: 0

Group type: COMPARATOR
Intervention: QLF
Number of subjects: 0
Study: 23868905

Group type: EXPERIMENTAL
Intervention: Pertuzumab with trastuzumab plus docetaxel
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo with trastuzumab plus docetaxel
Number of subjects: 0
Study: 20568384

Group type: EXPERIMENTAL
Intervention: Montelukast, 5 mg
Number of subjects: 154

Group type: COMPARATOR
Intervention: Salmeterol, 50 microg
Number of subjects: 154
Study: 18294411

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine 1 microg kg(‐1) over 10 min at anaesthesia induction followed by 0.4‐0.8 microg kg(‐1) h(‐1) infusion during maintenance
Number of subjects: 24

Group type: COMPARATOR
Intervention: Remifentanil 1 microg kg(‐1) over 1 min at anaesthesia induction followed by 0.2‐0.4 microg kg(‐1) min(‐1) infusion during maintenance
Number of subjects: 24
Study: 16274834

Group type: EXPERIMENTAL
Intervention: ISIS 14803 (0.5-3 mg/kg, thrice weekly for 4 weeks)
Number of subjects: 28
Study: 12846124

Group type: EXPERIMENTAL
Intervention: Tamoxifen
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Raloxifene (Evista)
Number of subjects: 0
Study: 11030202

Group type: EXPERIMENTAL
Intervention: 1-week course of oral prednisolone (PSL, 0.5 mg/kg)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: 2-week course of oral prednisolone (PSL, 0.5 mg/kg)
Number of subjects: 20
Study: 9010860

Group type: EXPERIMENTAL
Intervention: Camptosar (irinotecan)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Hycamtin (topotecan)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 9‐aminocamptothecin TM (9‐AC)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Taxotere (docetaxel)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Oncaspar
Number of subjects: 0
Study: 8476408

Group type: EXPERIMENTAL
Intervention: Behaviour therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Amitriptyline
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Psychodynamic psychotherapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Relaxation training (attention placebo)
Number of subjects: 0
Study: 3818148

Group type: COMPARATOR
Intervention: Ranitidine 150 mg
Number of subjects: 12

Group type: COMPARATOR
Intervention: Pirenzepine 50 mg
Number of subjects: 12

Group type: COMPARATOR
Intervention: Pirenzepine 50 mg plus Ranitidine 150 mg
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 31326936

Group type: EXPERIMENTAL
Intervention: Cuff Leak Test (CLT) results communicated to the bedside physician
Number of subjects: 100

Group type: COMPARATOR
Intervention: Cuff Leak Test (CLT) results not communicated to the treating physician
Number of subjects: 100
Study: 29972003

Group type: EXPERIMENTAL
Intervention: jinhuobu needling technique
Number of subjects: 54

Group type: COMPARATOR
Intervention: reinforcing needing technique achieved by rotating needle
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Both groups (before and after treatment)
Number of subjects: 54
Study: 26555329

Group type: EXPERIMENTAL
Intervention: Ranolazine
Number of subjects: 2604

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2604
Study: 26995808

Group type: EXPERIMENTAL
Intervention: Titanium-based FDPs
Number of subjects: 16

Group type: COMPARATOR
Intervention: Zirconia-based FDPs
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Both materials
Number of subjects: 16
Study: 22581424

Group type: EXPERIMENTAL
Intervention: Citrate replacement before and at the time of SWL in Group I (n: 20)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: SWL without any additional specific management for hypocitraturia in Group II (n: 20)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Normocitraturic cases as the control group (Group III; n: 20)
Number of subjects: 40
Study: 21280296

Group type: EXPERIMENTAL
Intervention: Antistax at a daily dose of 360 mg
Number of subjects: 119

Group type: EXPERIMENTAL
Intervention: Antistax at a daily dose of 720 mg
Number of subjects: 119
Study: 18375876

Group type: EXPERIMENTAL
Intervention: Dutch Geriatric Intervention Program (DGIP)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 0
Study: 16104439

Group type: EXPERIMENTAL
Intervention: 10 mg isobaric ropivacaine
Number of subjects: 50

Group type: COMPARATOR
Intervention: 8 mg isobaric ropivacaine plus 25 microg fentanyl
Number of subjects: 50
Study: 12005465

Group type: EXPERIMENTAL
Intervention: Infusion of standard parenteral nutrition (1.5-liter HPN formula, infused over 10 hours, approximately 25 kcal/kg/d with 30% lipid and 1.0 to 1.5 g/kg/d of protein)
Number of subjects: 5

Group type: COMPARATOR
Intervention: No infusion
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Infusion of standard parenteral nutrition
Number of subjects: 5
Study: 10099924

Group type: EXPERIMENTAL
Intervention: Pulmonary venous flow in hypertrophic cardiomyopathy patients
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Ratio of systolic to diastolic pulmonary venous flow velocity
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Ratio of velocity‐time integrals of both flow waves at atrial contraction
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Left atrial minimal volume
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Systolic fraction
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Pulmonary venous flow velocity pattern and left atrial size
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Pseudonormal mitral flow pattern
Number of subjects: 80
Study: 7770303

Group type: EXPERIMENTAL
Intervention: Dexamethasone (0.15 mg/kg every 6 hours for 4 days)
Number of subjects: 173

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 173

Group type: COMPARATOR
Intervention: Dexamethasone and Placebo
Number of subjects: 173
Study: 2180230

Group type: EXPERIMENTAL
Intervention: Live Shigella flexneri 2a and Shigella sonnei vaccine candidate strains with two virulence‐reducing markers
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ultrasonic lysates of vaccine candidate strains
Number of subjects: 0
Study: 298355

Group type: EXPERIMENTAL
Intervention: Zimelidine
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Desipramine
Number of subjects: 8
Study: 31977888

Group type: EXPERIMENTAL
Intervention: Cognitive rehabilitation (CCR) 3 times a week for 8 weeks plus neurologic music therapy (NMT) techniques, performed 3 times a week for 8 weeks.
Number of subjects: 30

Group type: COMPARATOR
Intervention: Conventional cognitive rehabilitation (CCR) 6 times a week for 8 weeks.
Number of subjects: 30
Study: 31476879

Group type: EXPERIMENTAL
Intervention: Isometric leg strength assessment at peak (7:00)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Isometric leg strength assessment at nadir (21:00)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Diurnal variation in isometric leg strength
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Day-to-day variation in isometric leg strength
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Isometric arm strength assessment at peak (7:00)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Isometric arm strength assessment at nadir (21:00)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Diurnal variation in isometric arm strength
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Day-to-day variation in isometric arm strength
Number of subjects: 19
Study: 29759709

Group type: EXPERIMENTAL
Intervention: Frequent vasovagal syncope (VVS) patients
Number of subjects: 24
Study: 27405522

Group type: EXPERIMENTAL
Intervention: Mentalization-based treatment in groups for 1 year
Number of subjects: 112

Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: Mentalization-based treatment in groups
Number of subjects: 112
Study: 25055821

Group type: EXPERIMENTAL
Intervention: Electroacupuncture for 8 weeks
Number of subjects: 560

Group type: COMPARATOR
Intervention: Prucalopride (2 mg once daily) for 32 weeks
Number of subjects: 560
Study: 21894485

Group type: EXPERIMENTAL
Intervention: d-amphetamine 20 mg
Number of subjects: 110

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 110
Study: 19505393

Group type: EXPERIMENTAL
Intervention: High dose sublingual‐swallow therapy (SLIT)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Subcutaneous immunotherapy (SCIT)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 17476875

Group type: EXPERIMENTAL
Intervention: SkinFold Thickness (SKF)
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: BMI-based estimation
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: BIA using Lukaski formula
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: BIA using Segal formula
Number of subjects: 41
Study: 16322140

Group type: EXPERIMENTAL
Intervention: Multisystemic therapy (MST) for approximately 6 months
Number of subjects: 127

Group type: EXPERIMENTAL
Intervention: Multisystemic therapy (MST)
Number of subjects: 127
Study: 12410756

Group type: EXPERIMENTAL
Intervention: Desmopressin therapy (with or without anticholinergic agents)
Number of subjects: 94

Group type: COMPARATOR
Intervention: Control group (continent controls)
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: NDE group (therapy‐resistant enuresis)
Number of subjects: 94
Study: 9530788

Group type: EXPERIMENTAL
Intervention: Clinician evaluation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Machine evaluation (Spinoscope)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Overall accuracy (Clinician vs Machine)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Machine's expert system
Number of subjects: 0
Study: 8914565

Group type: EXPERIMENTAL
Intervention: Various inspired fractions of oxygen before, during and after general anaesthesia
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Inspired oxygen fraction
Number of subjects: 15
Study: 2121203

Group type: COMPARATOR
Intervention: 100% oxygen
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: 50% nitrous oxide in oxygen
Number of subjects: 200
Study: 6101299

Group type: EXPERIMENTAL
Intervention: Neurolept anesthesia
Number of subjects: 20

Group type: COMPARATOR
Intervention: Enflurane anesthesia
Number of subjects: 20
Study: 29650683

Group type: EXPERIMENTAL
Intervention: Gemtuzumab ozogamicin (GO) 3 mg/m2 days 1, 4, and 7
Number of subjects: 0
Study: 26194249

Group type: EXPERIMENTAL
Intervention: Single-incision laparoscopic cholecystectomy (SILC)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Conventional laparoscopic cholecystectomy (CLC)
Number of subjects: 48
Study: 25528907

Group type: EXPERIMENTAL
Intervention: Permethrin-treated trousers
Number of subjects: 164

Group type: COMPARATOR
Intervention: Untreated trousers
Number of subjects: 164

Group type: EXPERIMENTAL
Intervention: Permethrin-treated trousers without cut protection lining
Number of subjects: 164

Group type: COMPARATOR
Intervention: Untreated trousers without cut protection lining
Number of subjects: 164

Group type: EXPERIMENTAL
Intervention: Permethrin-treated trousers with cut protection lining
Number of subjects: 164

Group type: COMPARATOR
Intervention: Untreated trousers with cut protection lining
Number of subjects: 164
Study: 21574832

Group type: EXPERIMENTAL
Intervention: 1% taurine-hydrated collagen membrane
Number of subjects: 16

Group type: COMPARATOR
Intervention: Saline-hydrated collagen membrane
Number of subjects: 16
Study: 20056195

Group type: EXPERIMENTAL
Intervention: Imaginal Exposure (IE)
Number of subjects: 255
Study: 18928735

Group type: EXPERIMENTAL
Intervention: Comprehensive education about the disease, drug therapy, diet, and telephonic strengthening
Number of subjects: 103

Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 103
Study: 15982148

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy (CBT)
Number of subjects: 143

Group type: EXPERIMENTAL
Intervention: Imipramine
Number of subjects: 143
Study: 12809846

Group type: EXPERIMENTAL
Intervention: Transarterial chemoembolization (TACE)
Number of subjects: 96

Group type: COMPARATOR
Intervention: Conservative treatment
Number of subjects: 96
Study: 10999261

Group type: EXPERIMENTAL
Intervention: Active school days (outdoor recess and physical education class)
Number of subjects: 76

Group type: COMPARATOR
Intervention: Restricted school days (indoor recess at a computer terminal, no physical education class)
Number of subjects: 76
Study: 8607955

Group type: EXPERIMENTAL
Intervention: Antibiotic ear drops (suspension of polymyxin B sulfate, neomycin sulfate, and hydrocortisone)
Number of subjects: 533

Group type: EXPERIMENTAL
Intervention: Prefabricated ear molds
Number of subjects: 533

Group type: COMPARATOR
Intervention: No precautions (control group)
Number of subjects: 533

Group type: EXPERIMENTAL
Intervention: Swimming (combined groups 1, 2, and 3)
Number of subjects: 533
Study: 1995088

Group type: EXPERIMENTAL
Intervention: Dexamethasone suppression test (DST) nonsuppression
Number of subjects: 77

Group type: COMPARATOR
Intervention: Normal DST results
Number of subjects: 77
Study: 6208248

Group type: EXPERIMENTAL
Intervention: neomycin (1 g/l) + bacitracin (50,000 IU/l) + clindamycin (900 mg/l)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: mezlocillin (4 g) + oxacillin (2 g) intravenously
Number of subjects: 90

Group type: COMPARATOR
Intervention: no antibiotics
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: none
Number of subjects: 90
Study: 31535722

Group type: EXPERIMENTAL
Intervention: Pectoral nerve-2 (PECS 2) block
Number of subjects: 80

Group type: COMPARATOR
Intervention: Serratus plane block
Number of subjects: 80
Study: 29913743

Group type: EXPERIMENTAL
Intervention: Standard Gynecological Treatment + Mensendieck Somatocognitive Therapy (MSCT)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Standard Gynecological Treatment (STGT)
Number of subjects: 40
Study: 27170790

Group type: EXPERIMENTAL
Intervention: Community engagement and planning (CEP)
Number of subjects: 1018

Group type: COMPARATOR
Intervention: Resources for services (RS)
Number of subjects: 1018
Study: 26071233

Group type: EXPERIMENTAL
Intervention: Intervention Group (IG) - initial visit with clinical history, electrocardiogram, instruction about pulse palpation and warning signs, and electrocardiogram every 6 months during a 2-year follow-up.
Number of subjects: 928

Group type: COMPARATOR
Intervention: Control Group (CG) - standard care without the intervention.
Number of subjects: 928
Study: 21875205

Group type: EXPERIMENTAL
Intervention: Self-prediction intervention asking participants to predict their future acceptance of HBV vaccination.
Number of subjects: 1175
Study: 20507380

Group type: EXPERIMENTAL
Intervention: Mechanical debridement with curettes
Number of subjects: 31

Group type: COMPARATOR
Intervention: Ultrasonic device
Number of subjects: 31
Study: 18337147

Group type: EXPERIMENTAL
Intervention: Magnesium sulphate (MgSO4) 0.1 mg/l (4g)
Number of subjects: 688

Group type: COMPARATOR
Intervention: Isotonic 0.9% saline (placebo)
Number of subjects: 688
Study: 15784715

Group type: EXPERIMENTAL
Intervention: Alendronate (10 mg daily)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Weight restoration
Number of subjects: 32
Study: 12056708

Group type: EXPERIMENTAL
Intervention: Eniluracil/5-fluorouracil (5-FU) regimen: 5-FU 1 mg/m2 twice daily + eniluracil 10 mg/m2 twice daily for 28 days
Number of subjects: 36
Study: 10078606

Group type: EXPERIMENTAL
Intervention: TA-GW vaccine (300 microg)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: TA-GW vaccine (0, 3, 30 microg)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Placebo (0 microg)
Number of subjects: 42
Study: 8575575

Group type: EXPERIMENTAL
Intervention: Indomethacin (100 mg.day‐1 for 4 days)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: OKY‐046 (400 mg.day‐1 for 4 days)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Indomethacin and OKY‐046
Number of subjects: 28
Study: 1817780

Group type: EXPERIMENTAL
Intervention: Fixation screws technique
Number of subjects: 2

Group type: COMPARATOR
Intervention: Tension bolt technique
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Both techniques
Number of subjects: 2
Study: 6874967

Group type: EXPERIMENTAL
Intervention: Videotape intervention for distressed couples
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Written feedback for distressed couples
Number of subjects: 58

Group type: COMPARATOR
Intervention: Placebo intervention for distressed couples
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Happy couples
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Negative behaviors of spouses
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Correlation of negative behaviors
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Ratings by spouses and observers
Number of subjects: 58
Study: 30542740

Group type: EXPERIMENTAL
Intervention: Hydrogen gas inhalation for 3 hours/day at home
Number of subjects: 55

Group type: COMPARATOR
Intervention: Chemotherapy (not specified)
Number of subjects: 55
Study: 29933407

Group type: EXPERIMENTAL
Intervention: IDEA protocol for structured expert elicitation
Number of subjects: 76